Sign in

QUCY on Nasdaq

Quantum Cyber N.V.

Quantum Cyber N.V. is a pharmaceutical preparations company based in Mainz, listed on Nasdaq (QUCY).1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with LIPELLA PHARMACEUTICALS INC., Silence Therapeutics or Trevena Inc, or pick any stock.

  • TickerQUCY on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersP71
  • Incorporated inNetherlands2
  • Business addressRobert Koch Strasse 50, Mainz2
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Quantum Cyber as a d/b/a until that time. In conjunction with the name change, we changed our Nasdaq ticker symbol to “QUCY”.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

72.6%Gross margin5
-3005.0%Operating margin5
-3018.3%Net margin5
-39.9%Revenue growth, 20255
-2526.6%Return on equity5
-$11.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue3¢$147.3K
  • Research and development97¢$4.9M

Out of $537.1K in revenue.5 The company lost money this year.

Financial statements

Revenue67895$537.1K in 2025+91% since 2019
0$250.0K$500.0K$750.0K$1.0M2019: $281.4K$281.4K20192020: $493.6K$493.6K2020+75%2021: $577.3K$577.3K2021+17%2022: $529.9K$529.9K2022−8%2023: $895.5K$895.5K2023+69%2024: $894.0K$894.0K2024−0%2025: $537.1K$537.1K2025−40%
Gross profit67895$389.8K in 2025
-$200.0K0$200.0K$400.0K$600.0K2019: -$61.3K-$61.3K20192020: $123.1K$123.1K20202021: $177.6K$177.6K2021+44%2022: $182.2K$182.2K2022+3%2023: $509.7K$509.7K2023+180%2024: $574.9K$574.9K2024+13%2025: $389.8K$389.8K2025−32%
Operating income67895-$16.1M in 2025+1651% since 2019
-$30.0M-$20.0M-$10.0M02019: -$921.9K-$921.9K20192020: -$673.7K-$673.7K2020−27%2021: -$9.7M-$9.7M2021+1343%2022: -$26.4M-$26.4M2022+172%2023: -$26.6M-$26.6M2023+1%2024: -$18.8M-$18.8M2024−30%2025: -$16.1M-$16.1M2025−14%
Net income67895-$16.2M in 2025+1594% since 2019
-$30.0M-$20.0M-$10.0M02019: -$957.1K-$957.1K20192020: -$586.9K-$586.9K2020−39%2021: -$11.7M-$11.7M2021+1892%2022: -$26.4M-$26.4M2022+126%2023: -$26.3M-$26.3M2023−0%2024: -$21.6M-$21.6M2024−18%2025: -$16.2M-$16.2M2025−25%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Total revenue$537.1K$894.0K
Cost of revenue$147.3K$319.1K
Gross profit$389.8K$574.9K
Sales and marketing$3.8M$6.6M
Research and development$4.9M$5.7M
Research and development related party$54.8K$121.2K
General and administrative (Note 2)$5.1M$6.7M
Impairment of intangible asset$2.6M
Restructuring expense$277.2K
Total operating expenses$16.5M$19.3M
Loss from operations-$16.1M-$18.8M
Other income$42.2K$90.6K
Government grant$533.5K$46.1K
Gain on sale of subsidiary$28.3K
Change in fair value of convertible debt$21.0K-$2.1M
Gain (loss) on sales and disposal of assets-$163.2K$46.8K
Interest expense-$373.5K-$945.5K
Other expense-$131.6K-$39.8K
Total other expense-$71.6K-$2.8M
Loss before income tax-$16.2M-$21.6M
Net loss-$16.2M-$21.6M
Foreign currency translation adjustment-$69.0K-$96.3K
Total comprehensive loss-$16.3M-$21.7M
Basic loss per ordinary share (in Dollars per share)-$2.70-$21.91
Diluted loss per ordinary share (in Dollars per share)-$2.70-$21.91
Basic Weighted average number of ordinary shares outstanding (in Shares)6.0M shares985.7K shares
Diluted Weighted average number of ordinary shares outstanding (in Shares)6.0M shares985.7K shares

Compare Quantum Cyber N.V. with another company

Corporate structure

Quantum Cyber N.V. sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Quantum Cyber N.V.

  • BP United Inc. Filed SCHEDULE 13G on Quantum Cyber N.V., latest Aug 10, 2026
  • David E. Lazar Filed SCHEDULE 13D/A on Quantum Cyber N.V., latest Aug 7, 2026 (2 filings since Apr 28, 2026)
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Quantum Cyber N.V., latest Feb 17, 2026 (4 filings since Feb 14, 2025)
  • Kevin Michael Donahue Filed SCHEDULE 13G/A on Quantum Cyber N.V., latest Jan 20, 2026 (2 filings since Jan 16, 2026)
  • KfW Filed SC 13G/A on Quantum Cyber N.V., latest Oct 7, 2024 (3 filings since Mar 1, 2023)
  • Hans Hekland Filed SC 13G on Quantum Cyber N.V., latest May 16, 2022
  • Moritz Eidens Filed SC 13G on Quantum Cyber N.V., latest May 16, 2022
  • Quantum Cyber N.V. P7
    • Mainz Biomed Germany GmbH Subsidiary · Germany
    • Mainz Biomed USA, Inc. Subsidiary · Nevada, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Quantum Cyber N.V. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Construction in progress$47.4K9 Dec 31, 2024
Property and equipment, before depreciation$1.8M5 Dec 31, 2025$1.8M5 Dec 31, 2024−4.2%
Accumulated depreciation$655.3K5 Dec 31, 2025$462.5K5 Dec 31, 2024+41.7%
Property and equipment, net$1.1M5 Dec 31, 2025$1.4M5 Dec 31, 2024−19.8%
Operating-lease assets (leased space)$1.3M5 Dec 31, 2025$1.1M5 Dec 31, 2024+16.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.2M9 Dec 31, 2024$7.1M9 Dec 31, 2023−11.8%
Stakes in other companies (equity method)$2.6M5 Dec 31, 2025

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$1.1M5 Dec 31, 2025$3.0M5 Dec 31, 2024−63.1%
Finite-lived intangibles, gross$1.1M5 Dec 31, 2025$3.8M5 Dec 31, 2024−70.5%
Accumulated amortization$754.4K5 Dec 31, 2024
Finite-lived intangibles, net$1.1M5 Dec 31, 2025$3.0M5 Dec 31, 2024−63.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$216.9K5 Dec 31, 2025$372.9K5 Dec 31, 2024−41.8%

Properties, in its own words

Our headquarters are located at Robert Koch Strasse 50, 55129 Mainz, Germany.

We do not currently own any real estate and do not intend to purchase any real estate in the near term.

Item 2 of the 10-K filed Mar 31, 2026.4

Leadership

Who has led Quantum Cyber N.V., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Guido Baechler2026
  2. David E. Lazar2026–now

Chief financial officer

  1. William J. Caragol2026–now
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerDarin Leigh named May 10, 202423
  • Executive Officer, DirectorMoritz Eidens named May 10, 202423
  • Executive OfficerPhillip Freese named May 10, 202423
  • DirectorAlberto Libanori named May 10, 202423
  • DirectorGregory Tibbits named May 10, 202423
  • DirectorNicole Holden named May 10, 202423

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Mainz Biomed Germany GmbH Germany3
  • Mainz Biomed USA, Inc. Nevada3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • MAINZ BIOMED N.V.Aug 25, 2021 to Apr 15, 20262
  • Mainz Biomed B.V.Aug 3, 2021 to Nov 12, 20212

Timeline

  1. Oct 9, 20268-K Entered a material agreement24
  2. Sep 25, 20268-K Regulation FD disclosure25
  3. Sep 25, 20268-K Financial statements and exhibits26
  4. Jul 24, 20268-K Regulation FD disclosure27
  5. Jul 16, 20268-K Completed an acquisition or sale; Regulation FD disclosure; Other events28
  6. Jul 7, 20268-K Executive or director change29
  7. Jul 1, 20268-K Entered a material agreement; Other events30
  8. Jun 26, 20268-K Change of auditor31
  9. Jun 15, 20268-K Entered a material agreement; Regulation FD disclosure32
  10. Jun 5, 20268-K Ended a material agreement33
  11. Jun 3, 20268-K Entered a material agreement; Regulation FD disclosure34
  12. May 28, 20268-K Other events35
  13. Apr 28, 2026New chief executive David E. Lazar becomes CEO13
  14. Jan 26, 2026New chief executive Guido Baechler becomes CEO12

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202636

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

198 filings to the SEC since October 2021: 5 annual reports, 2 quarterly reports, 22 major events, 35 insider forms, 14 large holders, 2 private raises, 118 other. The latest 20:

  1. Oct 9, 20268-K CURRENT REPORT EDGAR
  2. Oct 9, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  3. Sep 25, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
  4. Sep 25, 20268-K CURRENT REPORT EDGAR
  5. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  6. Aug 12, 20264 EDGAR
  7. Aug 10, 2026SCHEDULE 13G EDGAR
  8. Aug 7, 20264 EDGAR
  9. Aug 7, 2026SCHEDULE 13D/A EDGAR
  10. Aug 6, 20264/A EDGAR
  11. Aug 6, 20264/A EDGAR
  12. Aug 6, 20264/A EDGAR
  13. Aug 6, 20264/A EDGAR
  14. Aug 6, 20264/A EDGAR
  15. Aug 5, 20264 EDGAR
  16. Aug 4, 20264 EDGAR
  17. Aug 4, 20264 EDGAR
  18. Aug 4, 20264 EDGAR
  19. Aug 4, 20264 EDGAR
  20. Jul 24, 20268-K CURRENT REPORT EDGAR

The 198 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 17, 2025Donahue Kevin Michael10% ownerBuy685,000$1.51$1.0MForm 4
Oct 17, 2025Donahue Kevin Michael10% ownerBuy643,850$402,000.00$258.8BForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • BP United Inc.SCHEDULE 13G, 1 filing Aug 10, 202637
  • David E. LazarSCHEDULE 13D/A, 2 filings Apr 28, 2026 to Aug 7, 202638
  • ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 4 filings Feb 14, 2025 to Feb 17, 202639
  • Kevin Michael DonahueSCHEDULE 13G/A, 2 filings Jan 16, 2026 to Jan 20, 202640
  • KfWSC 13G/A, 3 filings Mar 1, 2023 to Oct 7, 202441
  • Hans HeklandSC 13G, 1 filing May 16, 202242
  • Moritz EidensSC 13G, 1 filing May 16, 202243

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Guido Baechler$225.0K$819.0K44
2025William Caragol59$175.0K$572.5K44
2024Chief Financial Officer$320.8K$681.6K44
2024Former ChiefExecutive Officer$420.0K$670.2K44

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jun 28, 2023Raised $14.3 million in a private offering of securities Form D: $50 million offered in all Form D

SEC filer profile

How Quantum Cyber N.V. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARQuantum Cyber N.V.1
  • CIK0001874252
  • Employer ID (EIN)00-00000004
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inNetherlands4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressRobert Koch Strasse 50, Mainz, Germany1
  • Phone49 6131 55428601
  • Shares outstanding84,068,192 as of Aug 13, 202611
  • Public float$5.7M as of Jun 30, 20254
  • AuditorReliant CPA PC, Newport Beach, CA PCAOB ID 6906; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceAug 3, 20211
  • Filings203 in all: 6-K (43), 8-K (21), 4 (17), CORRESP (14), 3 (11), 424B3 (8), 424B5 (8), EFFECT (8)1
    All 39 form types

    UPLOAD (8), 4/A (6), F-1/A (6), F-1 (5), 20-F (4), DRS (4), SCHEDULE 13G/A (4), SC 13G (3), SCHEDULE 13G (3), 10-Q (2), 144 (2), D (2), DEF 14A (2), F-3 (2), PRE 14A (2), S-8 (2), SC 13G/A (2), 10-K (1), 3/A (1), 8-A12B (1), 8-K/A (1), ARS (1), CERT (1), D/A (1), DRS/A (1), DRSLTR (1), FWP (1), NT 20-F (1), S-3 (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Jun 1, 2026
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary SharesQUCYNasdaq

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

Legal proceedings

On March 22, 2024, the Company filed a complaint in the Supreme Court of the State of New York against Boustead Securities, LLC, for breach of contract, unjust enrichment, and a declaratory judgment. Several weeks later, Boustead brought an arbitration against Mainz seeking to collect alleged unpaid compensation for financial services plus shares and warrants pursuant to two agreements. Mainz made an application to the Arbitration Panel requesting an order staying the Arbitration proceeding pending the courts’ final determination of the issues raised in the Supreme Court case, which was granted on September 12, 2024. Prior to the Court’s determination of which venue (the Supreme Court or FINRA Dispute Resolution) is proper to hear the dispute, Boustead agreed to withdraw the arbitration. Boustead then moved to dismiss Mainz’s claims but has not yet raised any claims in the court action against the Company. Thus, at this time there are no pending claims against the Company related to this action. Should Boustead eventually file claims against the Company, the Company would vigorously defend against all claims. Given that there are no pending claims, there is nothing to predict regarding a possible loss or range of loss that may result from this action. The Company does not believe that any outcome in this matter will have a material impact to its balance sheet or statement of operations in the future.

Except as set out above, we are not involved in, or aware of, any legal or administrative proceedings contemplated or threatened by any governmental authority or any other party. As of the date of this prospectus supplement, no director, officer or affiliate is a party adverse to us in any legal proceeding or has an adverse interest to us in any legal proceeding.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44